QVIDTVM Management LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), QVIDTVM Management LLC reported 14 stock positions worth $81.4 million. Its top holding was Bio-Rad Laboratories-A (BIO) at 28.7% of the portfolio, followed by Solventum (SOLV, 21.3%) and Amrize (AMRZ, 15.0%). Compared with Q4 2025, it opened 3 new positions, sold out of 2, added to 4 and reduced 3. The biggest buy was a new position in Oracle (ORCL) and the biggest sale an exit from Coty Class A (COTY).
- Most Recent 13F
- Q2 2026
- Location
- THE WOODLANDS, TX
- CIK
- 0001912226
- Portfolio Value
- $81.4M (Q1 2026)
- SEC Filing
- 0001912226-26-000002 ↗ filed May 15, 2026
Holdings Value
Holdings 14 stocks · $81.4M
| BIO Bio-Rad Laboratories-A | 28.68% | 83,732 | $23.3M | Add +0.3% |
| SOLV Solventum Corp. | 21.32% | 265,615 | $17.3M | Reduce -8.6% |
| AMRZ Amrize Ltd. | 14.97% | 217,456 | $12.2M | Add +0.4% |
| NBIS Nebius Group NV | 7.74% | 60,678 | $6.3M | Add +74.9% |
| ORCL Oracle Corp. | 7.03% | 38,902 | $5.7M | New |
| ZGN Ermenegildo Zegna NV | 6.73% | 525,893 | $5.5M | Add +10.5% |
| XRAY Dentsply Sirona Inc. | 5.49% | 385,409 | $4.5M | Reduce -20.6% |
| BRC INC-A | 3.24% | 3,400,681 | $2.6M | No change |
| ARE Alexandria Real Estate Equit | 2.28% | 40,000 | $1.9M | No change |
| HRB H&R Block Inc. filed as BLOCK H & R INC | 0.91% | 23,255 | $738K | New |
| WAB Wabtec Corp. | 0.85% | 2,770 | $692K | Reduce -18.6% |
| RTO Rentokil Initial PLC-SP ADR | 0.27% | 6,879 | $217K | No change |
| LAB Standard Biotools Inc. | 0.26% | 229,338 | $211K | No change |
| PM Philip Morris International | 0.22% | 1,079 | $178K | New |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 14 | $76.6M | BIO, NBIS, AMRZ, ORCL, SOLV |
| Q1 2026 | 14 | $81.4M | BIO, SOLV, AMRZ, NBIS, ORCL |
| Q4 2025 | 13 | $88.4M | BIO, SOLV, AMRZ, XRAY, ZGN |
| Q3 2025 | 8 | $92.9M | SOLV, BIO, COTY, XRAY, BRC INC-A |
| Q2 2025 | 8 | $99.8M | SOLV, BIO, COTY, XRAY, RTO |
| Q1 2025 | 8 | $113.1M | SOLV, BIO, RTO, COTY, XRAY |
| Q4 2024 | 8 | $124.2M | BIO, SOLV, RTO, BRC INC-A, XRAY |
| Q3 2024 | 8 | $142.9M | BIO, SOLV, WAB, RTO, XRAY |
| Q2 2024 | 7 | $125.0M | BIO, RTO, SOLV, WAB, BRC INC-A |
| Q1 2024 | 10 | $124.2M | BIO, RTO, WAB, BRC INC-A, XRAY |